The Effect of Osteoprotectin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) Gene Methylation on Aortic Valve Calcified

Table 1

Comparison of clinical and biochemical parameters in calcified group and noncalcified group.

Parameter	Noncalcified group ()	Calcified group ()	value
Gender [, (%)]			0.859
Male	13 (61.90%)	11 (64.71%)
Female	8 (38.10%)	6 (35.29%)
Age (year)			0.211
BMI (kg/m^2)			0.974
Smoking [, (%)]	9/42.86	7/41.18	0.917
CHD [, (%)]	2/9.52	3/17.65	0.640
Hypertension [, (%)]	10/47.62	9/52.94	0.744
Diabetes [, (%)]	3/14.29	1/5.88	0.613
MVD [, (%)]	2/9.52	1/5.88	1.000
LVEDD (mm)			0.389
Ejection fraction (%)			0.115
Aortic blood-flow velocity (m/s)			0.181
Mitral pressure gradient (mmHg)			0.239
Creatinine (mg/dL)			0.705
UA (μmol/L)			0.447
LDL-C (mmol/L)			0.232
CRP (mg/L)			0.592
Medication therapy [, (%)]
ACEI	8 (38.10%)	7 (41.18%)	0.847
Antihypertensive drugs	5 (23.81%)	5 (29.41%)	0.727
Statins	6 (28.57%)	10 (58.82%)	0.060
Diabetes treatment	3 (14.29%)	1 (5.88%)	0.613

CHD: coronary heart disease; mitral valve disease; LVEDD: left ventricular end-diastolic diameter; UA: uric acid; LDL-C: low-density lipoprotein cholesterol; CRP: C-reaction protein; ACEI: angiotensin converting enzyme inhibitor.